RT Journal Article
SR Electronic
T1 Multi-cohort analysis of host immune response identifies conserved protective and detrimental modules associated with severity irrespective of virus
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.10.02.20205880
DO 10.1101/2020.10.02.20205880
A1 Zheng, Hong
A1 Rao, Aditya M
A1 Dermadi, Denis
A1 Toh, Jiaying
A1 Jones, Lara Murphy
A1 Donato, Michele
A1 Liu, Yiran
A1 Su, Yapeng
A1 Karagiannis, Minas
A1 Marantos, Theodoros
A1 Hasin-Brumshtein, Yehudit
A1 He, Yudong D
A1 Giamarellos-Bourboulis, Evangelos J
A1 Heath, Jim
A1 Khatri, Purvesh
YR 2020
UL http://medrxiv.org/content/early/2020/10/05/2020.10.02.20205880.abstract
AB SARS-CoV-2 pandemic, the fourth pandemic of the decade, has underscored gaps in global pandemic preparedness and the need for generalizable tests to avert overwhelming healthcare systems worldwide, irrespective of a virus. We integrated 4,780 blood transcriptome profiles from patients infected with one of 16 viruses across 34 independent cohorts from 18 countries, and 71 scRNA-seq profiles of 264,224 immune cells across three independent cohorts. We found a myeloid cell-dominated conserved host response associated with severity. It showed increased hematopoiesis, myelopoiesis, and myeloid-derived suppressor cells with increased severity. We identified four gene modules that delineate distinct trajectories associated with mild and severe outcomes, and show the interferon response was decoupled from protective host response during severe viral infection. These modules distinguished non-severe from severe viral infection with clinically useful accuracy. Together, our findings provide insights into immune response dynamics during viral infection, and identify factors that may influence patient outcomes.Competing Interest StatementEJGB has received honoraria from Abbott CH, Angelini Italy, bioMerieux Inc, InflaRx GmbH, MSD Greece, and XBiotech Inc.; independent educational grants from AbbVie, Abbott, Astellas Pharma Europe, AxisShield, bioMerieux Inc, InflaRx GmbH, ThermoFisher Brahms GmbH, and XBiotech Inc; and funding from the FrameWork 7 program HemoSpec (granted to the National and Kapodistrian University of Athens), the Horizon2020 Marie-Curie Project European Sepsis Academy (granted to the National and Kapodistrian University of Athens), and the Horizon 2020 European Grant ImmunoSep (granted to the Hellenic Institute for the Study of Sepsis). PK is a shareholder and a consultant to Inflammatix, Inc. YH and YH are employees of, and stockholders in, Inflammatix, Inc.Funding StatementPK is funded in part by the Bill and Melinda Gates Foundation (OPP1113682); the National Institute of Allergy and Infectious Diseases (NIAID) grants 1U19AI109662, U19AI057229, and 5R01AI125197; Department of Defense contracts W81XWH-18-1-0253 and W81XWH1910235; and the Ralph & Marian Falk Medical Research Trust. AMR and YL are funded by National Science Foundation Graduate Research Fellowship. AMR is also funded by Stanford Graduate Fellowship. YL is also funded by the Knight-Hennessy Scholars Program. JT is funded by National Science Scholarship (PhD) from the Agency of Science, Technology, and Research (A*STAR), Singapore.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No IRB approval is required for this paper because aAll data used in this paper are already publicly available. No data were generated for the analyses in this paper.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are publicly available from public repositories of gene expression data including the Gene Expression Omnibus, EBI ArrayExpress, Sequence Read Archive, and others. The identifiers for each study are listed in Supplementary Table 1 and all figures.